| EMA number | EMEA/H/C/002611 |
| ATC code | N04BA02 |
| Authorisation | 19 November 2015 |
| Withdrawn | 2 April 2019 |
| Revision | 3 |
Symptomatic treatment of adult patients with Parkinson’s disease
INBRIJA — MERZ, approved 2026-07-07 (NDA209184).
49,822 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.